KATHRYN CLABORN: Open Payments
NPI 1295220549 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,018 in 114 payments from 20 companies in 2025. Trend: 2023 $1,576 · 2024 $1,643 · 2025 $2,018
Food & beverage: $2,018
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $369 |
| Dexcom, Inc. | 13 | $246 |
| BETA BIONICS, INC. | 14 | $240 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $182 |
| Corcept Therapeutics | 8 | $148 |
| Lilly USA, LLC | 8 | $128 |
| Insulet Corporation | 6 | $117 |
| Abbott Laboratories | 6 | $111 |
| Medtronic, Inc. | 4 | $83 |
| Esperion Therapeutics, Inc. | 4 | $60 |
Products named: Dexcom G6 Transmitter, iLet Bionic Pancreas, Kerendia, Ozempic, Korlym, Rybelsus, Omnipod, MOUNJARO.
Industry payments across LA — which companies pay providers there.
